Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Clazakizumab in Reducing hsCRP in Adults With Elevated hsCRP and Established ASCVD or at Increased Risk for ASCVD Events

NCT07783802 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07783802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07783802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Clazakizumab in Reducing hsCRP in Adults With Elevated hsCRP and Established ASCVD or at Increased Risk for ASCVD Events
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Recruiting
Start date
August 27, 2026
Completion date
October 31, 2027
Enrollment
120 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, cardiovascular disease, diabetes mellitus, type 2, hypertension, obesity, renal insufficiency, chronic